Pharma.ai, drug discovery engine, Insilico Medicine, Inc., Bethesda, Maryland, USA

[Airicist]

Developer - Insilico Medicine, Inc.

insilico.com/platform

pharma.ai

[Airicist]

Article "Tech-enabled drug discovery startup Insilico Medicine lands $225 million"
The company plans to use this money to use its therapeutics program in human clinical trials.

by Laura Lovett
June 22, 2021

[Airicist2]

Pharma.AI - the platform for target discovery, drug design, and clinical trial prediction

Nov 25, 2022

Alex Aliper, Co-Founder, President, and the Head of our R&D center in Abu Dhabi, talks about the development of Pharma.AI and how we've overcome industry challenges and bias to become a leader in the space of AI-driven therapeutic discovery and de novo small molecule design.

[Airicist2]

Pharma.AI Launch, November 14 2022

Nov 25, 2022

Since 2014, Insilico Medicine has pioneered the development of artificial intelligence (AI) platforms to accelerate the advancement of novel therapeutics into the clinic and into the hands of patients. After 8 years of extensive R&D with a robust team of drug hunters and AI scientists, we are excited to announce the paradigm shift that the full suite of Pharma.AI SaaS platform tools will bring to the industry.

This groundbreaking event will showcase Insilico Medicine's development of Pharma.AI and how we've overcome industry challenges and bias to become a leader in the space of AI-driven therapeutic discovery and de novo small molecule design.